Navigation Links
New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
Date:10/14/2010

INDIANAPOLIS, Oct. 14 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that a total of 14 U.S. and global studies involving its osteoporosis medications, FORTEO® [teriparatide (rDNA origin) injection] and EVISTA® (raloxifene HCl tablets), will be presented at the American Society for Bone and Mineral Research (ASBMR) 2010 Annual Meeting from October 15-19 in Toronto, ON, Canada.

In partnership with TransPharma Medical Ltd., Lilly conducted a Phase II study and will present an oral poster session comparing efficacy, safety and teriparatide pharmacokinetics of teriparatide delivered transdermally and via SQ injection in a three-month, randomized, multicenter study in postmenopausal women with osteoporosis.

Of the nine additional studies involving teriparatide, eight investigated the effects of the treatment, with three also testing safety.  Additional notes about teriparatide or raloxifene studies to be presented include:

  • One study used data from the teriparatide Fracture Prevention Trial to study the effect of body composition on bone.
  • Another study compared baseline characteristics, persistence to therapy and reasons for discontinuation between the Puerto Rican population and mainland United States population enrolled in a large observational study of teriparatide.
  • Two studies will be presented that investigated the Osteoporosis Patient Assessment Questionnaire (OPAQ) and were conducted using the Multiple Outcomes of Raloxifene Evaluation (MORE) trial database.
  • One study used data to develop a modified version of OPAQ, while another study examined the relationship between a comprehensive measure of risk of fracture, based on FRAX®, and health-related quality of life as measured by OPAQ.

  • The presentations are scheduled:

  • Comparison of Transdermal and subcutaneous teripa
    '/>"/>

  • SOURCE Eli Lilly and Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Frost & Sullivan Global Product Line Strategy of the Year Award Presented to Xenemetrix
    2. New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
    3. Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
    4. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    5. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
    6. Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010
    7. Promising New Therapy for Drug-Resistant Hypertension Presented at Interventional Cardiology Meeting in Washington, D.C.
    8. Mayo Clinic Research on SurgiCount To Be Presented at Conferences
    9. 2010 Prix Galien USA Pro Bono Humanum Award to be Presented to UNITAID for Work In Global HIV/AIDS Effort
    10. Results From Investigator-Sponsored Trials Presented at SSIEM Conference
    11. Webcast Alert: Isis Pharmaceuticals Hosts Expert Panel Conference Call to Discuss Mipomersen Data Presented at the ESC Congress 2010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/1/2015)... 2015  New York College of Health Professions announces ... portfolio with U.S. Patent #8,996,098 donated by its Chairman ... a surgical instrument that allows surgeons to view and ... in the traditional format of a slide that is ... during surgery, thus providing the surgeon real time analysis ...
    (Date:4/1/2015)... and MOUNTAIN VIEW, Calif. , ... BSX ) announces that it has signed ... venture-backed medical device company that develops, manufactures and ... guided transluminal drainage of targeted areas within the ... this week. The Xlumena portfolio ...
    (Date:4/1/2015)... April 1, 2015  The first national study ... supplements to treat attention-deficit/hyperactivity disorder (ADHD) among children ... of children with ADHD were receiving behavioral therapy ... Control and Prevention (CDC) study, "Treatment of Attention-Deficit/Hyperactivity ... published today in The Journal of Pediatrics ...
    Breaking Medicine Technology:Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3Boston Scientific Agrees to Acquire Xlumena 2Boston Scientific Agrees to Acquire Xlumena 3Boston Scientific Agrees to Acquire Xlumena 4Boston Scientific Agrees to Acquire Xlumena 5CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 2CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 3CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 4
    ... YORK, Dec. 29, 2010 Reportlinker.com announces that a ... Regenerative Medicine Markets ... way of treating injured and diseased human tissue by ... As such, astounding new advancements in the ability to ...
    ... 2010 Reportlinker.com announces that a new market ... 2010-2015 In-depth Research Report on China ... Report SummaryBased on the ... General Administration of Custom, Ministry of Commerce , ...
    Cached Medicine Technology:Reportlinker Adds Regenerative Medicine Markets 2Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry 2
    (Date:4/1/2015)... South Florida’s newest concept in retirement living, Casa ... from the State of Florida. This approval is ... retirement community that will offer a catered lifestyle designed ... America’s aging population is experiencing unprecedented growth but is ... according to a recent report by Harvard’s Joint Center ...
    (Date:4/1/2015)... April 01, 2015 IQ Formulations , ... and nutritional supplement companies in the U.S., today is commending ... and quality control standards for its herbal supplements.* GNC vowed ... chain to ensure the accuracy of labeling on its products. ... and IQ Formulations CEO Jay Cohen said: ...
    (Date:4/1/2015)... Dr. Rod J. Rohrich , ... of the Department of Plastic Surgery at UT Southwestern ... reports of blindness resulting from the use of ... published their study, along with ideas for treatment and ... "We began to see increasing reports of blindness as ...
    (Date:4/1/2015)... Senior Helpers of Central Texas ... of Choice Award by Home Care Pulse. The Best of ... to home care providers who receive the highest satisfaction scores ... in home care. This recognition reassures you that your home ... you with quality, trustworthy in home care. , In order ...
    (Date:4/1/2015)... SkillSurvey, the leading provider of hiring ... and the premiere provider of on-line automated reference checking ... webinar on “Using Big Data to Recruit Millennials.” The ... officer of MorseLife, a nationally recognized provider of health ... families in Palm Beach County. , “As the most ...
    Breaking Medicine News(10 mins):Health News:Casa Sant’Angelo Receives Approval for New Retirement Living 2Health News:IQ Formulations Applauds GNC for Enhancing Its Testing and Quality Control Processes for Herbal Supplements 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3Health News:Senior Helpers of Central Texas Awarded Prestigious 2015 Senior Home Care Provider of Choice Award from Home Care Pulse 2Health News:SkillSurvey Hiring Expert Series Continues with Webinar Featuring MorseLife 2Health News:SkillSurvey Hiring Expert Series Continues with Webinar Featuring MorseLife 3
    ... risk by 26%, study finds , , TUESDAY, Aug. 5 (HealthDay News) ... you smarter, as your grandmother said, but by lowering the risk ... a new study. , The benefit appears to come from fish ... tuna three times a week can reduce the risk of dementia ...
    ... May Need a Liver ... Transplant, SACRAMENTO, Calif., Aug. ... she heads to the Mrs.,America* competition in Tucson, Arizona on September 2, she ... Connor will be,healthy again. Connor was born with a deadly liver disease -- ...
    ... CINCINNATI, Aug. 5 The Procter & Gamble,Company (NYSE: ... the April -,June quarter to $21.3 billion and nine percent ... sales were up five percent for both,the quarter and the ... in which P&G delivered top-line growth at or above the,company,s ...
    ... Advice to Las Vegas, SCARBOROUGH, N.Y., Aug. 5 ... turning to Bald Girls Do Lunch(R) for cool options,and ... organization,is bringing women with alopecia areata together for the ... The August 15 Las Vegas event is a ...
    ... aims to give back to Mercy Ships , ... Garden Valley. TX ... of Britain,s greatest medal hopes at the Beijing Olympics, racer Paul Goodison, ... provides free medical care to the people of Africa. , , , ...
    ... QHR client hospital Gritman Medical Center and its ... Hospital, were recently ranked number one in a ... Services (CMS) in "overall patient satisfaction" in the ... to sharing number one rankings, the hospitals also ...
    Cached Medicine News:Health News:Fish May Ward Off Dementia and Stroke 2Health News:Fish May Ward Off Dementia and Stroke 3Health News:Mrs. California Uses Her Title to Save Lives - She Now Heads to Mrs. America Competition 2Health News:Mrs. California Uses Her Title to Save Lives - She Now Heads to Mrs. America Competition 3Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 2Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 3Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 4Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 5Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 6Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 7Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 8Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 9Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 10Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 11Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 12Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 13Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 14Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 15Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 16Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 17Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 18Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 19Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 20Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 21Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 22Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 23Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 24Health News:Too Hot for Wigs: Bald Women Go Natural in Nevada 2Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 2Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 3Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 4Health News:Collaborative Efforts Prove Effective for QHR Client Hospital Gritman Medical Center and Neighboring Pullman Regional Hospital 2Health News:Collaborative Efforts Prove Effective for QHR Client Hospital Gritman Medical Center and Neighboring Pullman Regional Hospital 3
    ... an ELISA method for the qualitative detection of ... in human serum. When the EBNA IgG test ... as the EBV viral capsid IgG or IgM, ... the results can serve as an aid in ...
    ... VCA IgM Test is an ELISA method for ... Virus viral capsid antigen (VCA) in human serum. ... conjunction with other testing such as the EBV ... antigen tests and/or heterophile tests, the results can ...
    ... ImmunoDOT Borrelia (Lyme) test is ... test for the qualitative detection ... (anti-P39) and related Borrelia burgdorferi ... are detected in serum as ...
    ... Tests are qualitative enzyme immunoassays (EIA) for ... (IgG or IgM, respectively) in serum. Equivocal ... be supplemented with a standardized western blot ... to support a clinical diagnosis of B. ...
    Medicine Products: